Voltage-gated sodium channels (Na~v~s) are mainstays of neuronal function, and mutations in the genes encoding CNS Na~v~s (Na~v~1.1 \[*SCN1A*\], Na~v~1.2 \[*SCN2A*\], Na~v~1.3 \[*SCN3A*\], and Na~v~1.6 \[*SCN8A*\]) are causes of some of the most common and severe genetic epilepsies and epileptic encephalopathies (EE).^[@R1]^ Fibroblast-growth-factor homologous factors (FHFs) compose a family of 4 proteins that interact with the C-terminal tails of Na~v~s to modulate the channels\' fast, and long-term, inactivations.^[@R2]^ *FHF2* mutation is a rare cause of generalized epilepsy with febrile seizures plus (GEFS+).^[@R3]^ Recently, a de novo *FHF1* mutation (p.R52H) was reported in early-onset EE in 2 siblings.^[@R4]^ We report 3 patients from unrelated families with the same *FHF1* p.R52H mutation. The 5 cases together frame the FHF1 R52H EE from infancy to adulthood. As discussed below, this gain-of-function disease may be amenable to personalized therapy.

Patient 1 (P1, [table](#T1){ref-type="table"}) is a 3-year-old boy. Convulsive seizures began on day 2 of his life and remain intractable, with frequent status epilepticus (SE) manifesting as generalized or right-sided facial seizures. His EEGs show slow backgrounds and multifocal epileptiform discharges (figure e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000115)). Multiple antiepileptic drug (AED) regimens failed, but he is currently at his best on a combination of the ketogenic diet and medications indicated in the [table](#T1){ref-type="table"}. He has severe global developmental delay, is nonverbal, has poor visual and social interaction, just started rolling slightly and sitting with support, and is tube-fed. He has generalized hypotonia with head lag and does not track. He suffers from chronic constipation. MRI at onset was normal, and at 2 years revealed widened ventricles and pericerebral CSF spaces (figure e-2A).
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Phenotypic features of 5 patients with FHF1 R52H epileptic encephalopathy
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Patient 2 (P2) is a 16-year-old girl with intractable seizures since age 6 weeks and frequent SE. Seizures included generalized tonic-clonic (GTC) and partial seizures with left-sided facial twitching and lip-smacking (figure e-3). Phenytoin has been part of her AEDs, and relatively efficacious, since age 6 years. Since age 7, she develops 24 hours of severe ataxia after every GTC, which then gradually improves. Vagal nerve stimulation substantially improved seizure, and ataxia, intensities, and frequencies. MRI at 16 months was unremarkable but at 8 years showed cerebellar atrophy (figure e-2B). She suffers from chronic constipation. She has severe cognitive impairment with single words, has normal motor development, and ambulates. She needs help with all activities of daily living.

Patient 3 (P3) is an 18-year-old girl with intractable epilepsy since day 2 of her life with frequent SE. Seizures include leftward head deviation followed by generalized convulsion. EEGs were slow with multifocal spikes in infancy and Lennox-Gastaut--like in early childhood. She suffers from chronic constipation, hypohydrosis, and reduced lacrimation, suggesting autonomic dysfunction. She has moderate intellectual disability and can read simple books. She ambulates with a spastic circumductive gait and has substantial heel cord tightness. Current therapies ([table](#T1){ref-type="table"}) include vagal nerve stimulation. MRI at present shows bilateral mesial temporal sclerosis and mild prominence of cerebellar folia, findings not present in MRIs from early childhood (figure e-2C).

All 3 patients had the same de novo *FHF1* NM_004113.5:c.155G\>A, p.R52H mutation detected by whole-exome or whole-genome sequencing and confirmed by Sanger sequencing, and no other relevant de novo change. The [table](#T1){ref-type="table"} summarizes their clinical features and those of the recently published^[@R4]^ original sib-pair. Salient features of the latter pair include neonatal-onset intractable epilepsy, profound intellectual disability, severe feeding difficulties, MRI initially unremarkable and subsequently exhibiting cerebellar atrophy, ataxia, and death in SE.^[@R4]^

Based on 5 patients, the core FHF1 R52H disease comprises neonatal-onset persistent intractable epilepsy and moderate-to-severe intellectual disability. Radiologically, neurodegeneration, especially cerebellar, is present, which, beyond a mutational consequence appears to be aggravated by the severity and frequency of SE. It may also be exacerbated by treatment of SE. All 4 patients with cerebellar atrophy, including the original 2, were on phenytoin ([table](#T1){ref-type="table"}), repeatedly loaded and subsequently chronically maintained because of relative success in SE management and prevention. It may be cautious to use alternative medications, where possible, until this putative phenytoin cerebellar iatrogenicity is clarified.

Siekierska et al.^[@R4]^ demonstrated in vitro and in vivo that R52H is a toxic gain-of-function mutation. To date, thousands of patients with EE have undergone exome sequencing. Our rare finding of an FHF1 mutation suggests that FHF1 R52H might be a mutation-specific disease. It is possible that future *FHF1* mutations with similar effects will be identified, but these would be expected to act through similar gain-of-function mechanisms. As such, methods to downregulate the R52H and related alleles, e.g., with allele-specific antisense oligonucleotides, could prove therapeutic in this catastrophic encephalopathy.

Supplementary Material
======================

###### Data Supplement

###### DDD coinvestigators

Supplemental data at [Neurology.org/ng](10.1212/NXG.0000000000000115)

Author contributions: Dr. Al-Mehmadi, Dr. Splitt, Dr. Ramesh, Dr. DeBrosse, Dr. Dessoffy, Dr. Xia, Dr. Yang, and Dr. Rosenfeld: acquisition of data and analysis and interpretation. Dr. Cossette and Dr. Michaud: study concept and design. Dr. Hamdan and Dr. Campeau: study concept and design, analysis and interpretation, and critical review of the manuscript for important intellectual content. Dr. Minassian: study concept and design, acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content, and study supervision.

Study funding: This work was supported by Genome Canada, Genome Quebec, the Ontario Brain Institute, and the DDD Study. The DDD Study presents independent research commissioned by the Health Innovation Challenge Fund (grant HICF-1009-003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (grant WT098051). The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health.

*Disclosure: Dr. Al-Mehmadi, Dr. Splitt, and Dr. Ramesh report no disclosures. Dr. DeBrosse receives funding from NIH 2U54 NS078059-04 and NIH U54NS078059-04; receives philanthropic funding from families of individuals with pyruvate dehydrogenase complex deficiency; has received funding for a trip from the Alternating Hemiplegia of Childhood Foundation; and has received royalty payments from Decision Support in Medicine, LLC. Dr. Wallis reports no disclosures. Dr. Xia has been an employee of Baylor Genetics LLC. Dr. Yang reports no disclosures. Dr. Rosenfeld has served on the editorial boards of* Prenatal Diagnosis and Molecular Syndromology*; has been an employee of Signature Genomic Laboratories, PerkinElmer, Inc.; and has received research support from NIH/National Human Genome Research Institute. Dr. Cossette receives funding from UCB Pharmaceuticals, Genome Quebec, Genome Canada, CIHR, and the Savoy Foundation. Dr. Michaud receives funding from Genome Quebec and Genome Canada. Dr. Hamdan reports no disclosures. Dr. Campeau serves on the editorial boards of Scientific Reports and the* Journal of Pediatric Genetics*; has acted as a consultant for Alexion Pharmaceuticals and Biomarin; holds stock options in Illumina, Inc.; and receives funding from the CHU Sainte-Justine Research Center, the Canadian Institutes of Health Research, the Fonds de Recherche en Sante Quebec, the Resaeau de Sante Buccodentaire et Osseuse, and the Fondation du Grand Defi Pierre Lavoie. Dr. Minassian receives funding from Genome Canada and the Ontario Brain Institute; holds patents for diagnostic testing of the following genes: EPM2A, EPM2B, MECP2, and VMA21; and has received license fee payments and royalty payments for the aforementioned patents. Go to* [*Neurology.org/ng*](10.1212/NXG.0000000000000115) *for full disclosure forms. The Article Processing Charge was paid by the authors.*

Disclaimer: The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from genetic testing offered at the Baylor Miraca Genetics Laboratories.

Acknowledgment: The study has UK Research Ethics Committee\'s approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research through the Comprehensive Clinical Research Network, the Health Innovation Challenge Fund (grant HICF-1009-003), and the Wellcome Trust Sanger Institute (grant WT098051). BAM holds the University of Toronto Michael Bahen Chair in Epilepsy Research. The authors thank the Next Generation Sequencing/bioinformatics teams at McGill University, the Genome Quebec Innovation Center, the Réseau de Médecine Génétique Appliquée, and Drs. Ledia Brunga (DNA sample management); Dipayan Mitra (MRI); Ms. Gail Charlton (EEG); and Ms. Sylvia Dobrzeniecka (sequencing) for their efforts.

[^1]: Member of the DDD Study group.

[^2]: Directors of CENet.

[^3]: *DDD Study coinvestigators are listed at* [*Neurology.org/ng*](10.1212/NXG.0000000000000115).
